

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT7897830

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
MATHIEU PERREE	03/15/2016
ALLAN E. HALLQUIST	03/15/2016
OLIVER PETIT	03/15/2016
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	DIATECH ONCOLOGY LLC
<b>Street Address:</b>	405 DUKE DRIVE, SUITE 240
<b>City:</b>	FRANKLIN
<b>State/Country:</b>	TENNESSEE
<b>Postal Code:</b>	37067
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
Application Number:	16591389
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(617)570-1231
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	6175701000
<b>Email:</b>	us-patentbos@goodwinlaw.com, MGustafson@goodwinlaw.com, JasonWilliams@goodwinlaw.com
<b>Correspondent Name:</b>	GOODWIN PROCTER LLP
<b>Address Line 1:</b>	100 NORTHERN AVENUE
<b>Address Line 2:</b>	IP DOCKETING DEPT./7TH FL
<b>Address Line 4:</b>	BOSTON, MASSACHUSETTS 02210
<b>ATTORNEY DOCKET NUMBER:</b>	DTO-001C2
<b>NAME OF SUBMITTER:</b>	MEGAN A. GUSTAFSON
<b>SIGNATURE:</b>	/Megan A. Gustafson/
<b>DATE SIGNED:</b>	04/12/2023
<b>Total Attachments: 5</b>	
source=DTO-001 Inventor Assignment to Diatech Oncology LLC#page1.tif	
source=DTO-001 Inventor Assignment to Diatech Oncology LLC#page2.tif	

source=DTO-001 Inventor Assignment to Diatech Oncology LLC#page3.tif

source=DTO-001 Inventor Assignment to Diatech Oncology LLC#page4.tif

source=DTO-001 Inventor Assignment to Diatech Oncology LLC#page5.tif

**PATENT**

**REEL: 063304 FRAME: 0738**

**ASSIGNMENT AND CONFIRMATION OF ASSIGNMENT  
OF PATENT RIGHTS**

WHEREAS, We, Mathieu Perrée, Allan E. Hallquist, and Olivier Petit, have invented one or more inventions described in United States Application No. 13/803,623, filed March 14, 2013, entitled "SYSTEM AND METHOD FOR AUTOMATED DETERMINATION OF THE RELATIVE EFFECTIVENESS OF ANTI-CANCER DRUG CANDIDATES" (hereinafter, the "Patent Application"); and

WHEREAS, DiaTech Oncology LLC (hereinafter "ASSIGNEE"), a corporation having a place of business at 405 Duke Drive, Suite 240, Franklin, TN 37067 and successor-in-interest to DiaTech Oncology LLC, desires to acquire and/or confirm the acquisition of our entire interest in said invention(s) and said Patent Application, and applications and Letters Patent(s) which claim priority to or the benefit of said Patent Application;

NOW, THEREFORE, to all whom it may concern, be it known that for and in consideration of said agreements and of other good and valuable consideration, the receipt of which is hereby acknowledged, we confirm we have sold, assigned and transferred and by these presents do hereby sell, assign and transfer unto said ASSIGNEE, its successors, assigns, and legal representatives, our entire right, title and interest in and throughout the United States of America, its territories and all foreign countries, in and to the invention(s) described in said Patent Application, together with our entire right, title and interest in and to said Patent Application and such Letters Patent(s) as may issue thereon or claim priority under United States law or international convention (including International Application No. PCT/US2013/039189, filed May 2, 2013), including but not limited to non-provisionals, continuations, divisionals, reissues, reexaminations, extensions, and substitutions of said Patent Applications or such Letters Patent(s), and any right, title and interest we may have in provisional applications to which said Patent Application claims priority (including U.S. Provisional Patent Application No. 61/641,610, filed May 2, 2012); said invention(s), application(s) and Letters Patent(s) to be held and enjoyed by said ASSIGNEE for its own use and behalf and for its successors, assigns and legal representatives, to the full end of the term for which said Letters Patent(s) may be granted as fully and entirely as the same would have been held by us had this assignment and sale not been made; we hereby convey all of our rights arising under or pursuant to any and all United States laws and international agreements, treaties or laws relating to the protection of industrial property by filing any such applications for Letters Patent(s), including but not limited to any cause(s) of action and damages accruing prior to this assignment;

AND, we hereby further agree for ourselves and our executors and administrators to execute upon request any other lawful documents and likewise to perform any other lawful acts which may be deemed necessary to secure fully the aforesaid invention(s) to said ASSIGNEE, its successors, assigns, and legal representatives, but at its or their expense and charges;

AND, we hereby authorize and request the Director of the United States Patent and Trademark Office and the empowered officials of all other governments to issue such Letters Patent(s) as shall be granted upon or claim priority to or the benefit of said Patent Application, or applications based thereon, to said ASSIGNEE, its successors, assigns, or legal representatives.


IN TESTIMONY WHEREOF, we have hereunto set our hands and affixed our seals on  
the date(s) set forth below:


  
\_\_\_\_\_  
Mathieu Perrée (Assignor)

Date: 15 MARCH 2016

Witness:


15 MARCH 2016  
Date

  
\_\_\_\_\_  
Signature  
CASSANDRE LEONGSON  
Printed Name


  
Allan E. Hallquist (Assignor)

Date: 15 MARCH 2016

Witness:  
15 March 2016  
Date

  
Signature


SMANTI HEATHCOCK  
Printed Name

  
\_\_\_\_\_  
Olivier Petit (Assignor)

Date: 15 MARCH 2016


Witness:

15 MARCH 2016  
Date

  
\_\_\_\_\_  
Signature

KASSANORE LEONGSON  
Printed Name

DiaTech Oncology LLC (Assignee)

By: 

Print Name: Robert E Henry

Title: President & CEO

Date: 03/15/2016

ACTIVE/85438977.1